Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson bought 101,119 shares of the business’s stock in a transaction on Monday, November 16th. The stock was purchased at an average price of $7.42 per share, for a total transaction of $750,302.98. Following the purchase, the chief executive officer directly owned 635,456 shares in the company, valued at approximately $4,715,083.52. This represents a 18.92% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Troy Edward Wilson also recently made the following trade(s):
- On Friday, November 13th, Troy Wilson purchased 98,881 shares of Kura Oncology stock. The shares were purchased at an average cost of $7.63 per share, with a total value of $754,462.03.
- On Monday, August 24th, Troy Wilson purchased 100,000 shares of Kura Oncology stock. The shares were acquired at an average cost of $12.39 per share, with a total value of $1,239,000.00.
Kura Oncology Price Performance
NASDAQ KURA opened at $7.09 on Tuesday. The company has a quick ratio of 4.71, a current ratio of 3.60 and a debt-to-equity ratio of 0.07. Kura Oncology, Inc. has a 12-month low of $6.75 and a 12-month high of $13.90. The company has a market capitalization of $651.43 million, a PE ratio of -2.15 and a beta of 0.56. The firm’s 50 day moving average is $10.05 and its 200-day moving average is $9.76.
Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. The business had revenue of $22.84 million for the quarter, compared to analyst estimates of $24.94 million. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.20 earnings per share for the current fiscal year.
Institutional Trading of Kura Oncology
A number of large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its position in shares of Kura Oncology by 32.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in shares of Kura Oncology by 69.7% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after purchasing an additional 233,633 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $12,735,000. Great Lakes Advisors LLC bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $2,851,000. Finally, Tidal Investments LLC bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $1,029,000.
Wall Street Analysts Forecast Growth
KURA has been the topic of several recent research reports. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Thursday. Citizens Jmp restated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, October 15th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.88.
Read Our Latest Analysis on Kura Oncology
About Kura Oncology
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Further Reading
- Five stocks we like better than Kura Oncology
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
